Health Shop
The finest nutraceuticals and supplements from around the world — every product personally vetted by me with proven efficacy. From Tibetan adaptogens to South American antioxidants.
«Every product in this collection was carefully selected over years of testing on myself and my patients»
— md_pereligynFind Your Goal
Choose your goal — we'll show the right products
Where to start in your case
Write what troubles you most — I will show what in the catalogue relates to it.
Product Catalog
OKI (ketoprofen lysine salt) 80 mg sachets
💊 Ketoprofen in its lysine salt — granules for oral solution, for pain and fever. ▪︎ Ketoprofen lysine salt 80 mg per sachet, equivalent to 50 mg ketoprofen ▪︎ Manufacturer: Dompé ▪︎ In Italy 68 of the 105 registered oral packs are sold without prescription; in Germany oral ketoprofen is prescription-only without exception 🔬 How it works: a non-selective NSAID, and the lysine salt is what makes this form worth naming. Ketoprofen itself is poorly soluble and irritating to the gastric mucosa; bound to lysine it dissolves at once and is absorbed within minutes, which is why the granules act faster than a tablet of the same substance. The dose to compare is the base: 80 mg of the salt is 50 mg of ketoprofen. 📊 Evidence: in the Cochrane single-dose review ketoprofen 50 mg gave an NNT of 2.9 (95% CI 2.4-3.7) — and that average describes nobody. In dental pain it was 1.8, at the level of the strongest drug in the group; in other surgery 4.2. The difference is significant at P below 0.00006 and the review authors call the gap unusual. This is a drug whose figure depends on the kind of pain, not on the dose. ⚠️ Chosen by a physician. Class cautions apply in full: stomach, kidneys, blood pressure, heart. Where it is sold over the counter the packs are sized for days, not weeks. Never combine with another NSAID. 📦 Ordered on request via chat — availability and delivery are confirmed by the administrator. Full guide: /en/blog/ketoprofen-dental-pain-and-everything-else
Synflex (naproxen sodium) 550 mg tablets
💊 Prescription long-acting NSAID for pain and inflammation. ▪︎ Naproxen sodium 550 mg tablets, equivalent to 500 mg naproxen; taken twice daily ▪︎ In Italy 550 mg is prescription-only (Synflex); the over-the-counter naproxen there is Momendol 220 mg 🔬 How it works: pharmacologically naproxen is an ordinary non-selective NSAID — its distinction is not the mechanism but the clock. Its half-life is markedly longer than that of the others in this group, so one tablet covers about twelve hours and the day needs two doses rather than three or four. For pain that lasts days that changes more than a decimal place on any strength table. 📊 Evidence: in the Cochrane single-dose review naproxen 500/550 mg gave an NNT of 2.7 (95% CI 2.3-3.2) — mid-table among the five. But that metric is computed over six hours after a single dose, so it cannot see duration of action at all. Naproxen looks average in it precisely because the thing it does best falls outside the measurement. ⚠️ Prescription-only at this strength, chosen by a physician. Class cautions apply in full: stomach, kidneys, blood pressure, heart. A common mistake is to take a 550 mg tablet on top of an over-the-counter 220 mg one — that is the same drug twice. Never combine with another NSAID. If pain outlasts the pack, that is a reason to see a doctor rather than buy another box. 📦 Ordered on request via chat — availability and delivery are confirmed by the administrator. Full guide: /en/blog/naproxen-long-acting-relief-in-acute-pain
Novalgina (metamizole) 500 mg tablets
💊 Prescription non-opioid analgesic and antipyretic. ▪︎ Metamizole sodium 500 mg tablets ▪︎ Manufacturer: Sanofi ▪︎ Prescription-only in Italy and Germany; withdrawn in the United States, the United Kingdom, Sweden and Australia, and without a valid authorisation in France 🔬 How it works: metamizole is not a classical NSAID. It has almost no anti-inflammatory action, and its analgesia is built differently — its active metabolites act largely within the central nervous system and it relaxes smooth muscle, which is why it works where an ordinary anti-inflammatory does not: colic, spasm, pain from a hollow organ. That is its place in the cabinet, not a higher rung on a strength ladder. 📊 Evidence: in the Cochrane single-dose review metamizole 500 mg gave an NNT of 2.4 (95% CI 1.8-3.1). That interval is the widest of the five and spans both the top and the bottom of the list — the evidence base here is the thinnest, not the strongest. ⚠️ Prescription-only, chosen by a physician. The known risk is agranulocytosis — very rare, no more than 1 in 10,000, but abrupt. The European Rote-Hand letter of 9 December 2024 abandoned routine blood monitoring precisely because the reaction develops faster than a scheduled test would catch it, and tightened the contraindications instead. Stop at once and have a full blood count taken for: fever, chills, sore throat, or painful sores in the mouth, nose, throat, genital or anal area. On antipyretic use and while on antibiotics these signs can be masked. 📦 Ordered on request via chat — availability and delivery are confirmed by the administrator. Full guide: /en/blog/metamizole-dipyrone-strength-and-agranulocytosis
Voltfast (diclofenac potassium) 50 mg sachets
💊 Prescription diclofenac in its potassium salt — powder for oral solution, for acute pain. ▪︎ Diclofenac potassium 50 mg per sachet, dissolved in water ▪︎ Manufacturer: Novartis ▪︎ In Italy the 50 mg strength is prescription-only; 25 mg forms are sold over the counter 🔬 How it works: the molecule that reaches the inflammation is the same whichever salt carries it — the salt decides how fast it gets there. The potassium salt dissolves and is absorbed quickly, which is what acute pain needs; the sodium salt was built for sustained release and reaches its peak slowly. In chronic pain that is an advantage. In a single dose for pain that already hurts, it is the whole problem. 📊 Evidence: in the Cochrane single-dose review diclofenac potassium 50 mg gave an NNT of 2.1 (95% CI 1.9-2.5), while the sodium salt in the same setting gave 6.6 — a threefold gap for one active substance. The review authors write plainly that the sodium salt has limited efficacy and should probably not be used in acute pain. The box says one word, diclofenac; the result depends on the word after it. ⚠️ Prescription-only at this strength, chosen by a physician. Diclofenac carries a higher cardiovascular risk than some others in its class — this matters in ischaemic heart disease, after stroke and in heart failure. Class cautions apply in full: stomach, kidneys, blood pressure. Over-the-counter courses of diclofenac are limited to days, not weeks. Never combine with another NSAID. 📦 Ordered on request via chat — availability and delivery are confirmed by the administrator. Full guide: /en/blog/diclofenac-potassium-versus-sodium-difference-in-strength
Arcoxia (etoricoxib) 90 mg tablets
💊 Prescription selective COX-2 inhibitor for the relief of acute and chronic pain. ▪︎ Etoricoxib 90 mg film-coated tablets, once daily; the range also holds 30, 60 and 120 mg ▪︎ Developed by Merck ▪︎ Not approved in the United States; authorised across the EU, in Italy all 384 registered packs are prescription-only 🔬 How it works: the two cyclooxygenases do different jobs. COX-1 works in the stomach lining and platelets all the time; COX-2 is switched on where inflammation begins. Non-selective drugs block both, which is why the stomach pays for the analgesia. Etoricoxib is the most selective of the licensed coxibs and leaves COX-1 largely alone — the trade-off is that the same selectivity shifts the balance between clotting and its restraint, which is where the cardiovascular caution comes from. 📊 Evidence: in the Cochrane single-dose review the NNT for etoricoxib 120 mg was 1.8 (95% CI 1.7-2.0) — the best figure of the five non-opioid analgesics in this catalogue. Read what that number does and does not mean before comparing: it describes a single dose in acute postoperative pain over four to six hours, not strength in general. ⚠️ Prescription-only, chosen by a physician. In the EU the 120 mg dose is licensed for an acute gout attack alone and for a short course; 90 mg is the standard analgesic strength. The EU label contraindicates etoricoxib in uncontrolled hypertension — blood pressure must be measured before starting and checked during treatment. Class cautions apply in full: stomach, kidneys, blood pressure, heart. Never combine with another NSAID: the analgesia does not add up, the risk does. 📦 Ordered on request via chat — availability and delivery are confirmed by the administrator. Full guide: /en/blog/etoricoxib-arcoxia-acute-postoperative-pain
MOTS-c 10 mg pre-filled pen
🧬 Mitochondrial-derived peptide MOTS-c, 10 mg in a GoQuick pre-filled pen (10 mg / 2 ml), for subcutaneous use. ▪︎ Sixteen amino acids encoded in the 12S rRNA region of mitochondrial DNA — the first known regulator of ageing written in the mitochondrial genome rather than the nuclear one ▪︎ Research-use product, not a registered medicine 🔬 How it works: MOTS-c interferes with the folate cycle, AICAR accumulates and the master energy sensor AMPK switches on — the same lever physical exertion pulls. Glucose moves into skeletal muscle more readily, fat oxidation rises and mitochondrial biogenesis starts, which is why the peptide is described as an exercise mimetic. Under metabolic stress it also travels into the cell nucleus and switches on stress-adaptation genes: a signal running from mitochondrion to nucleus rather than the other way. ⚠️ Research-status product, not a registered medicine: selection, dose and combinations are decided by a physician. Not for pregnancy, breastfeeding or uncontrolled chronic illness, and not a replacement for training — the peptide amplifies a signal the body normally gets from exertion. Basic bloodwork and a doctor's opinion first. 📦 Ordered on request via chat — availability and delivery are confirmed by the administrator. Full guide: /en/blog/mots-c-mitochondrial-peptide-exercise-and-metabolism
Givlaari (givosiran) 189 mg vial for injection
💊 Prescription ALAS1-directed small interfering RNA for the treatment of adults with acute hepatic porphyria. ▪︎ Givosiran 189 mg/mL, one single-dose vial; 2.5 mg/kg subcutaneously once monthly, administered by a healthcare professional ▪︎ Manufacturer: Alnylam Pharmaceuticals ▪︎ FDA approval: November 2019 🔬 How it works: haem is assembled in a chain of eight steps, and in this disease one step works poorly. Finished haem normally restrains the first enzyme of the chain, ALAS1, by feedback; when haem falls short that restraint loosens, the chain accelerates and runs into the fault, so unfinished intermediates pile up in front of it. Two of them — aminolevulinic acid and porphobilinogen — are toxic to the nervous system and are what the attacks are made of. Givosiran silences ALAS1 in liver cells, holding the first enzyme quietened continuously so the intermediates never accumulate. Intravenous hemin breaks an attack that has begun; this drug prevents it from starting. 📊 Evidence: in ENVISION (NEJM 2020) in 94 patients the annualised attack rate was 3.2 versus 12.5 on placebo — 74% lower (p<0.001) — with lower urinary intermediates, fewer days of hemin use and better daily pain scores. At the 36-month final analysis (J Hepatol 2023), 86% of patients on continuous treatment and 92% of those crossed over from placebo had no attacks at all, and annualised days of hemin use fell from 16.2 to 0.4. ⚠️ Prescription-only, given by a healthcare professional with support for anaphylaxis at hand; severe hypersensitivity to givosiran is the only contraindication. There is no boxed warning, but six precautions apply: anaphylaxis, hepatic toxicity (liver tests at baseline and periodically; dose reduced to 1.25 mg/kg after significant elevations), changes in renal function, injection-site and recall reactions, raised homocysteine (measure at baseline, consider vitamin B6) and pancreatitis — the last being easy to mistake for another porphyria attack. It does not replace hemin for an attack in progress, nor the avoidance of triggering drugs, fasting and alcohol. 📦 Ordered on request via chat — availability and current price are confirmed by the administrator.
Oxlumo (lumasiran) injection, single-dose vial
💊 Prescription HAO1-directed small interfering RNA for primary hyperoxaluria type 1, to lower urinary and plasma oxalate in paediatric and adult patients with no lower age limit. ▪︎ Lumasiran 94.5 mg/0.5 mL, one single-dose vial; subcutaneous injection on a loading-then-maintenance schedule — three monthly loading doses, then maintenance dosing (3 mg/kg every three months from 20 kg) ▪︎ Manufacturer: Alnylam Pharmaceuticals ▪︎ FDA approval: November 2020 🔬 How it works: in type 1 disease a fault in the AGXT gene leaves the liver unable to convert glyoxylate into harmless glycine, so it is oxidised into oxalate instead — a metabolic dead end the body can neither break down nor reuse, leaving the kidneys as the only exit, where it precipitates with calcium. Lumasiran does not touch the broken enzyme. It silences the HAO1 messenger RNA in liver cells, lowering glycolate oxidase — the intact enzyme one step above that supplies glyoxylate. Less raw material reaches the fault, so the fault stops mattering, and the mechanism is independent of which AGXT mutation the patient carries. 📊 Evidence: in ILLUMINATE-A (NEJM 2021) in 39 patients aged 6 and over, 24-hour urinary oxalate fell by 65.4%, a difference from placebo of 53.5 percentage points (p<0.001), visible within a month; 84% reached excretion no higher than 1.5× the upper limit of normal versus 0% on placebo. Over 60 months (CJASN 2026) the reduction held at 54%, estimated GFR stayed stable and nephrocalcinosis grade improved in 21 of 28 patients. ⚠️ Prescription-only, prescribed by a nephrology centre. It is ineffective in primary hyperoxaluria types 2 and 3, whose pathways the mechanism does not touch, and in secondary hyperoxaluria. The drug reduces oxalate production but does not dissolve existing stones, and stopping treatment restores production. The label carries no boxed warning, no contraindications and no warnings section; injection-site reactions are the only common adverse reaction. 📦 Ordered on request via chat — availability and current price are confirmed by the administrator.
Revuforj (revumenib) 110 mg tablets
💊 Prescription menin inhibitor for relapsed or refractory acute leukaemia with a KMT2A translocation in patients from one year of age, and for relapsed or refractory acute myeloid leukaemia with a susceptible NPM1 mutation where no satisfactory alternative exists. ▪︎ Revumenib 110 mg film-coated tablets, bottle of 30; taken every 12 hours in 28-day cycles (270 mg twice daily from 40 kg, or 160 mg twice daily with a strong CYP3A4 inhibitor) ▪︎ Manufacturer: Syndax Pharmaceuticals ▪︎ FDA approval: November 2024, indication extended in 2025 🔬 How it works: in KMT2A-rearranged leukaemia the fusion protein keeps the genes of cellular immaturity switched on, so the cell is stuck as a blast and cannot mature. It reaches that DNA with the help of menin, an ordinary cellular protein acting as its guide. Revumenib wedges between menin and KMT2A and breaks the bond: the immaturity programme switches off and leukaemic cells begin maturing into normal blood cells. The mechanism is differentiating, not cytotoxic, and the same dependence on menin exists in NPM1-mutated disease. 📊 Evidence: in AUGMENT-101 (JCO 2025) among 57 evaluable KMT2A-translocated patients complete remission or complete remission with partial haematologic recovery reached 22.8% against a 10% hypothesis (p=0.0036), with an overall response of 63.2% and no detectable residual disease in 15 of 22 responders. In the NPM1 cohort (Blood 2025) the rate was 23.4% (p=0.0014), overall response 46.9%, median remission 4.7 months, and 5 of 30 responders proceeded to transplantation. ⚠️ Prescription-only, prescribed by a haemato-oncology centre. The FDA boxed warning covers differentiation syndrome, which can be fatal and occurred in 25% of patients (33% in KMT2A-translocated myeloid leukaemia), and QTc prolongation with torsades de pointes. Treatment requires a confirmed KMT2A translocation or susceptible NPM1 mutation, is not started with QTcF above 450 msec or white cells above 25 Gi/L, and continues at least six months. In most cases it serves as a bridge to stem cell transplantation rather than an alternative to it. 📦 Ordered on request via chat — availability and current price are confirmed by the administrator.
Forzinity (elamipretide) 280 mg vials for injection
💊 Prescription cardiolipin-binding peptide indicated to improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg. ▪︎ Elamipretide 280 mg/3.5 mL (80 mg/mL), carton of 4 single-patient-use vials; 40 mg subcutaneously once daily at the same time each day ▪︎ Manufacturer: Stealth BioTherapeutics ▪︎ FDA approval: September 2025 🔬 How it works: the inner mitochondrial membrane is held in shape by cardiolipin, a wedge-shaped lipid that keeps the respiratory chain complexes in working position. In Barth syndrome a fault in the TAZ gene disables tafazzin, the enzyme that matures cardiolipin, so an intermediate form accumulates and the membrane loses its geometry. Elamipretide is a four-amino-acid peptide that binds cardiolipin and stabilises that geometry — it does not repair the gene and does not create normal cardiolipin, it braces a structure whose internal fastening has worn out. 📊 Evidence: in the randomised crossover part of TAZPOWER (Genet Med 2021) in 12 patients both primary endpoints were missed. In the open-label extension walking distance improved by 95.9 m at week 36 and by 96.1 m at week 168 (Genet Med 2024). Against 19 untreated patients matched by propensity score (Orphanet J Rare Dis 2022) the difference was 79.7 m at week 64 and 91.0 m at week 76, with muscle strength 40.8 and 56.7 newtons greater; left ventricular stroke volume rose in the treated and fell in the untreated. ⚠️ Prescription-only, prescribed by a specialist centre; genetic confirmation of the diagnosis is required. Approval is accelerated on an intermediate endpoint (knee extensor strength) and the indication is narrow — to improve muscle strength, not to treat the syndrome; a confirmatory trial is pending. The product contains benzyl alcohol and must never be used in neonates, and intravenous administration is not approved. Not established below 30 kg; the dose is reduced in severe renal impairment. In a large randomised trial in primary mitochondrial myopathy the same drug showed no effect. 📦 Ordered on request via chat — availability and current price are confirmed by the administrator.
Sephience (sepiapterin) 1000 mg oral powder
💊 Prescription oral powder for hyperphenylalaninaemia in adults and children from one month of age with sepiapterin-responsive phenylketonuria, used together with a phenylalanine-restricted diet. ▪︎ Sepiapterin 1,000 mg per unit-dose packet, carton of 30 packets; taken once daily with food, the powder mixed into water or apple juice ▪︎ Manufacturer: PTC Therapeutics ▪︎ FDA approval: July 2025 🔬 How it works: phenylalanine hydroxylase cannot work without its cofactor, tetrahydrobiopterin (BH4). In many patients the enzyme is damaged but not dead — it simply holds the cofactor poorly. The previous-generation drug sapropterin is BH4 itself, an unstable molecule that enters cells only to a limited extent. Sepiapterin is the natural precursor of BH4: it enters the cell by its own route and is converted into the cofactor inside, which is why blood levels of sepiapterin itself stay below 2% of the BH4 formed from it. 📊 Evidence: in APHENITY (Lancet 2024) blood phenylalanine in responders fell by 63% over six weeks versus a 1% rise on placebo, a difference of 395.9 μmol/L (p<0.0001); 114 of 156 participants responded to the 14-day trial course. Head to head against the maximum licensed dose of sapropterin (Metabolism 2026) the reduction was 437.0 versus 256.6 μmol/L, 70% greater. In the extension (Genet Med 2026) dietary phenylalanine tolerance rose from 27.6 to 62.5 mg/kg per day over 26 weeks. ⚠️ Prescription-only, directed by a physician experienced in PKU. It does not replace the diet — the indication requires both. Response must be established by a trial course; patients with primary BH4 deficiency (GCH1, PTS, QDPR, SPR, PCBD1) were excluded from the trials. The label carries no boxed warning but three precautions: increased risk of bleeding, excessive lowering of phenylalanine in some children, and an interaction with levodopa. An effect on cognitive outcomes has not been demonstrated directly. 📦 Ordered on request via chat — availability and current price are confirmed by the administrator.
Galafold (migalastat) 123 mg capsules
💊 Prescription oral pharmacological chaperone for adults with a confirmed diagnosis of Fabry disease and an amenable GLA gene variant. ▪︎ Migalastat 123 mg hard capsules, carton of 14 with a punch-out dosing calendar; one capsule every other day on an empty stomach ▪︎ Manufacturer: Amicus Therapeutics ▪︎ FDA approval: August 2018 🔬 How it works: in Fabry disease a faulty GLA gene leaves cells short of alpha-galactosidase A, and globotriaosylceramide accumulates in the kidneys, heart, vessels and nerve ganglia. Enzyme replacement therapy delivers a manufactured enzyme intravenously every two weeks; migalastat delivers nothing new. With many mutations the enzyme is assembled but comes out unstable, so the cell destroys it as defective before it reaches the lysosome. Migalastat sits in the active site and holds the protein in the correct shape, letting it pass quality control and arrive at its workplace, where the acidic environment and excess substrate displace it again. 📊 Evidence: in FACETS (NEJM 2016) the primary endpoint was not met — 41% responders versus 28% on placebo (p=0.30) — because patients with non-amenable variants had been enrolled; among the amenable, left ventricular mass index fell by 7.7 g/m² over 24 months and estimated GFR changed by −0.30 mL/min/1.73 m² per year. In ATTRACT (J Med Genet 2017) 57 adults switched from infusions: renal function changed comparably, left ventricular mass index fell by 6.6 g/m² while it did not change significantly on enzyme replacement therapy. ⚠️ Prescription-only, prescribed by a specialist centre. An amenability assay of the GLA variant is mandatory before treatment — of 600 disease-causing mutations tested, 268 proved amenable, and the drug cannot work without one. It replaces enzyme replacement therapy rather than being added to it. Not studied and not recommended below an eGFR of 30 mL/min/1.73 m² or on dialysis, nor established in patients under 18. Approval was accelerated on a substrate surrogate; an effect on dialysis, infarction and stroke has not been demonstrated. 📦 Ordered on request via chat — availability and current price are confirmed by the administrator.
Path to Health
The shop is the third step in the body recovery system
Diagnostics
Comprehensive examination and tests to understand the body's condition
"Without understanding the root cause, it's impossible to find the right solution"
Program
Individual plan for recovery and health support
"The program is your personal map to health, tailored to your body"
Shop
Quality supplements to implement your program
"Only the products I use myself and recommend to patients"Message the curator
A Week with the Curator
How I use supplements from my collection throughout the day
Morning
Awakening and activation
"I start the morning with adaptogens — they gently boost energy without a caffeine crash"
Afternoon
Focus and productivity
"In the middle of the day, it's important to support cognitive function without overstimulation"
Evening
Recovery and relaxation
"In the evening, the body should prepare for sleep — it's time for restorative nutrients"